We got here throughout a bullish thesis on IQVIA Holdings Inc. on Rebound Capital’s Substack. On this article, we’ll summarize the bulls’ thesis on IQV. IQVIA Holdings Inc.’s share was buying and selling at $191.15 as of August 22nd. IQV’s trailing and ahead P/E have been 27.70 and 16.21 respectively in response to Yahoo Finance.
ESB Skilled/Shutterstock.com
IQVIA Holdings has established itself as a number one enabler for pharmaceutical and healthcare firms by combining information, expertise, and outsourced experience to speed up drug improvement and commercialization. Its largest enterprise, Analysis & Growth Options (55% of income), manages the end-to-end scientific trial course of, from examine design and affected person recruitment to information evaluation and regulatory filings, permitting drugmakers to concentrate on core R&D.
Expertise & Analytics Options (40% of income) monetizes IQVIA’s huge repository of de-identified healthcare information, offering insights to optimize trial design, monitor outcomes, and help commercialization. The remaining Contract Gross sales & Medical Options (5% of income) focuses on the ultimate stage of drug launches by offering software program and personnel help for gross sales execution.
Following a 200% surge from 2020 to 2021, the inventory has undergone a protracted drawdown over the previous three years, largely pushed by a biotech funding downturn between 2022 and 2024. This stoop constrained financing for small and mid-cap biotech firms, delaying or cancelling trials and weighing on backlog conversion throughout the outsourced scientific analysis sector, dampening sentiment towards IQVIA.
Nonetheless, with the Federal Reserve signaling price cuts, the prospect of a renewed biotech funding cycle may present a tailwind. Even with out that catalyst, IQVIA’s fundamentals stay stable: its R&DS backlog stands at $32.1 billion, with $8.1 billion anticipated to transform over the subsequent 12 months, guaranteeing visibility into near-term income progress.
Additional strengthening its positioning, IQVIA has resolved long-running authorized disputes with Veeva and entered into long-term scientific and business collaborations. This alignment permits IQVIA to run trials on Veeva’s Medical Suite and combine its analytics with Veeva purposes underneath streamlined third-party entry, enabling joint offers and simpler cross-selling. These developments enhance execution capability, deepen consumer stickiness, and set the stage for each natural progress restoration and a number of enlargement.
Beforehand we coated a bullish thesis on ICON Public Restricted Firm (ICLR) by DeepValue Capital in April 2024, which highlighted its scalable CRO mannequin, sturdy backlog, and long-term trial demand. The inventory has depreciated about 60% since, as biotech funding pressures weighed on sentiment. The thesis nonetheless stands given pipeline wants. Rebound Capital shares the same view with IQVIA, emphasizing information scale and Veeva decision.
